Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Ontogeny of Valproic Acid Disposition and Metabolism: A Developmental Study in Postnatal Lambs and Adult Sheep

Harvey Wong, Sanjeev Kumar, Dan W. Rurak, Eddie Kwan, Frank S. Abbott and K. Wayne Riggs
Drug Metabolism and Disposition August 2000, 28 (8) 912-919;
Harvey Wong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjeev Kumar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan W. Rurak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eddie Kwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank S. Abbott
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Wayne Riggs
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The ontogeny of valproic acid (VPA) disposition and metabolism was investigated in developing lambs and adult sheep (Dorset or Suffolk breed). Specifically, we wished to investigate the role of glucuronidation and β-oxidation on VPA elimination during development. Catheters were implanted in a carotid artery, a jugular vein, and the urinary bladder in 10-day-old (10 d;n = 8), 1-month-old (1 M; n = 4), and 2-month-old lambs (2 M; n = 5). In adult sheep (n = 5), catheters were implanted in a femoral artery and vein. After the administration of a 10 mg/kg VPA i.v. bolus, serial blood samples and cumulative urine samples were collected for 36 h in the adult ewes and for 72 h in the lambs. Due to saturable protein binding, age-related differences in VPA clearance were more obvious when examining the total body clearance of unbound drug (Clutb). Mean Clutb increased significantly with age up to 2 months (10 d = 2.65 ± 1.16 ml/min/kg; 1 M = 5.11 ± 2.49 ml/min/kg; 2 M = 12.84 ± 3.88 ml/min/kg) before decreasing to adult levels (7.73 ± 2.64 ml/min/kg). Similarly, the urinary recovery of the major metabolite, VPA-glucuronide, was significantly less in 10 d lambs (29.2 ± 16.0% of the dose) when compared with the adult and 2 M groups (both ∼74% of the dose). No differences with age were observed in the portion of the dose excreted as the β-oxidation metabolite, 2-n-propyl-3-oxopentanoic acid. The results suggest that alterations in Clutb with age may be attributable to postnatal development of enzymes involved in VPA glucuronidation.

Footnotes

  • Send reprint requests to: Dr. K.W. Riggs, Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall, Vancouver, B.C., Canada V6T 1Z3. E-mail: riggskw{at}unixg.ubc.ca

  • ↵1 A part of this work was presented at the 1999 Annual Meeting of the American Association of Pharmaceutical Scientists (1999 Nov 14–18, New Orleans, LA) and is abstracted in Pharm Sci Suppl1:S-222.

  • These studies were supported by funding from the Medical Research Council of Canada. H.W. was the recipient of a Pharmaceutical Manufacturers Association of Canada/Health Research Foundation and Medical Research Council of Canada Graduate Scholarship in Pharmacy. S.K. was the recipient of a University of British Columbia Graduate Fellowship. D.W.R. is the recipient of an investigatorship award from the British Columbia Children's Hospital Foundation.

  • Abbreviations used are::
    VPA
    valproic acid
    10 d
    10-day-old lambs
    1 M
    1-month-old lambs
    2 M
    2-month-old lambs
    AUCo-∞
    area under the curve of arterial plasma concentration-time profile
    AUMCo-∞
    area under the first-moment curve
    Clr
    renal clearance
    Clur
    renal clearance for unbound VPA
    Cltb
    total body clearance of the total drug
    Clutb
    total body clearance based on unbound drug concentrations
    Cmax
    maximal plasma concentration
    fp
    area weighted unbound fraction of the drug
    MRT
    mean residence time of the total drug
    MRTu
    mean residence time of the unbound drug
    t1/2β
    terminal elimination half-life of total drug,tu1/2β, terminal elimination half-life of unbound drug
    tmax
    time of occurrence of maximal plasma concentration
    Vdss
    steady-state volume of distribution
    Vdss′
    steady state volume of distribution corrected for the effects of saturable protein binding
    Vduss
    steady-state volume of distribution for the unbound drug
    (E)-2-ene VPA
    2-n-propyl-2-pentenoic acid
    3-ene VPA
    2-n-propyl-3-pentenoic acid
    4-ene VPA
    2-n-propyl-4-pentenoic acid
    3-keto VPA
    2-n-propyl-3-oxopentanoic acid
    4-keto VPA
    2-n-propyl-4-oxopentanoic acid
    3-OH VPA
    3-hydroxy VPA
    4-OH VPA
    4-hydroxy VPA
    5-OH VPA
    5-hydroxy VPA
    2-PSA
    2-propylsuccinic acid
    2-PGA
    2-propylglutaric acid
    • Received December 24, 1999.
    • Accepted May 2, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 28 (8)
Drug Metabolism and Disposition
Vol. 28, Issue 8
1 Aug 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ontogeny of Valproic Acid Disposition and Metabolism: A Developmental Study in Postnatal Lambs and Adult Sheep
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
Citation Tools
Research ArticleArticle

Ontogeny of Valproic Acid Disposition and Metabolism: A Developmental Study in Postnatal Lambs and Adult Sheep

Harvey Wong, Sanjeev Kumar, Dan W. Rurak, Eddie Kwan, Frank S. Abbott and K. Wayne Riggs
Drug Metabolism and Disposition August 1, 2000, 28 (8) 912-919;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Ontogeny of Valproic Acid Disposition and Metabolism: A Developmental Study in Postnatal Lambs and Adult Sheep

Harvey Wong, Sanjeev Kumar, Dan W. Rurak, Eddie Kwan, Frank S. Abbott and K. Wayne Riggs
Drug Metabolism and Disposition August 1, 2000, 28 (8) 912-919;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Abundant expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1 and xCT transporters in blood-arachnoid barrier of pig, and polarized localizations at CSF- and blood-facing plasma membranes
  • Pharmacokinetics of Organic Cation Transporter 1 (OCT1) Substrates in Oct1/2 Knockout Mice and Species Difference in Hepatic OCT1-mediated Uptake
  • Human Cytochrome P450 1A1 Adapts Active Site for Atypical Nonplanar Substrate
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics